首页>
外国专利>
NOP RECEPTOR AGONISTS FOR THE TREATMENT OF L-DOPA INDUCED DYSKINESIAS
NOP RECEPTOR AGONISTS FOR THE TREATMENT OF L-DOPA INDUCED DYSKINESIAS
展开▼
机译:NOP受体激动剂用于治疗L-多巴诱发的运动障碍
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to the chronic treatment with L,3-4-dihydroxyphenylalanine (L-DOPA). Chronic L-DOPA administration still represents the most effective pharmacological therapy of Parkinson's disease (PD) although it is invariably associated with the appearance (within 5-10 years after start of the therapy, in about 80 % of patients) of motor complications that limit its clinical effectiveness and greatly reduce the quality of life of patients (Obeso et al., 2000). These motor complications encompass motor fluctuations (e.g. wearing off and 'on-off fluctuations) and abnormal involuntary movements or dyskinesias (peak dose and diphasic dyskinesias, dystonia). We report for the first time that in an animal model of dyskinesias, administration of agonists at nociceptin/orphanin FQ receptors, termed NOP receptors, dramatically reduces abnormal involuntary movements induced by L-DOPA administration. NOP receptor agonists thus represent a novel class of drugs useful for the treatment of L-DOPA induced dyskinesias.
展开▼